After nearly 50 years of therapeutic application of neuroleptics, diagnosis and classification of neuroleptic-induced extrapyramidal syndromes still concentrate on their "neurological" (motor) aspects. Psychiatric (mental) aspects are in general - if at all - regarded as “secondary” to motor symptoms. Psychiatric side effects of neuroleptics (including psychotic exacerbations during neuroleptic treatment) have, however, anecdotally been reported since 1954 but never developed into a systematic classification. Accordingly, psychiatric manifestations of extrapyramidal side effects frequently are overlooked, misdiagnosed as psychotic deteriorations and treated by increased dosing of neuroleptics instead anticholinergics, which in addition are falsly suspected of bearing a high addictive potential and the risk of development of tardive dyskinesia. It is suggested that neuroleptic-induced basal ganglia dysfunction results in motor as well as mental extrapyramidal side effects, whose recognition and management is essential to achieve better tolerability of and thereby compliance with neuroleptic treatment.
References
-
1
Adler L A, Angrist B, Reiter S. et al .
Neuroleptic-induced akathisia: a review.
Psychopharmacology.
1989;
97
1-11
-
2
Adler L A, Angrist B, Fritz P. et al .
Lack of efficacy of d-propranolol in neuroleptic-induced akathisia.
Neuropsychopharmacology.
1991;
4
109-115
-
3 Arnold O H. Schizophrene Exazerbationen: paradoxe Reaktionen auf Intensiv-Neuroleptika. In Kryspin-Exner K, Hinterhuber H, Schubert H, Hrsg. Therapie akuter psychiatrischer Symptome. Schattauer Stuttgart; 1979: 165-168
-
4
Ayd F J.
A survey of drug-induced extrapyramidal reactions.
JAMA.
1961;
175
1054-1060
-
5
Casey D E.
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
Schizophr Res .
1991;
4
109-120
-
6
Casey D E.
Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.
Psychopharmacology.
1994;
112 Suppl
S55-59
-
7
Casey D E.
Extrapyramidal Syndromes. Epidemiology, Pathophysiology and the Diagnostic Dilemma.
CNS Drugs.
1996;
5 Suppl 1
1-12
-
8
Chouinard G, Jones B D.
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics.
Am J Psychiat.
1980;
137
16-21
-
9
Conrad K, Domanovsky K, Wieser S.
Über extrapyramidale Anfallszustände bei Behandlung mit Phenothiazinen.
Neurologie.
1956;
9
505-512
-
10
Coyle J T, Price D L, DeLong M R.
Alzheimer's disease: a disorder of cortical cholinergic innervation.
Science.
1983;
219
1184-1190
-
11
Degkwitz R.
Die psychische Eigenwirkung der Psychodysleptika.
Hippokrates.
1966;
8
285-290
-
12 Delay J, Deniker P. Le traitement des psychoses par une methode neurolytique derivée de l'hibernotherapy. (Le 4560 R.P. utilisé seul en cure prolongée et continue). Compt rend du Congr des Médecines Alienistes et Neurologistes Luxembourg; 1952
-
13
Delay J, Deniker P.
Chlorpromazine and neuroleptic treatments in psychiatry.
J Clin Exp Psychopathol Q Rev Psych Neurol.
1956;
17
19-24
-
14
Dose M.
Gibt es ein Abhängigkeitspotential der Anticholinergika?.
TW Neurologie Psychiatrie.
1993;
7
11-13
-
15 Dose M. Anticholinergika in der Psychiatrie. In Barocka A, Hrsg. Psychopharmakotherapie in Klinik und Praxis. Schattauer Stuttgart; 1998: P. 86-93
-
16
Fleischhacker W W, Barnas C, Guenther V. et al .
Mood-altering efects of biperiden in healthy volunteers.
J Aff Dis.
1987;
12
153-157
-
17
Fleischhacker W W, Roth S D, Kane J M.
The pharmacologic treatment of neuroleptic-induced akathisia.
J Clin Psychopharmacol.
1990;
10
12-21
-
18
Freyhan F A.
Psychomotility and parkinsonism in treatment with neuroleptic drugs.
Arch Neurol Psychiat.
1957;
78
465-472
-
19
Gerlach J, Korsgaard S, Clemmesen P. et al .
The St. Hans rating scale for extrapyramidal syndromes: reliability and validity.
Acta Psychiatr Scand.
1993;
87
244-252
-
20
Gerlach J, Larsen E B.
Subjective experience and mental side-effects of antipsychotic treatment.
Acta Psychiatr Scand.
1999;
99 (Suppl.395)
113-117
-
21 Haag H, Rüther E, Hippius H. Tardive Dyskinesia. WHO Expert Series on Biological Psychiatry. Hogrefe & Huber Vol. I Seattle; 1992
-
22
Haase H -J.
Psychiatrische Erfahrungen mit Megaphen (Largactil) und dem Rauwolfiaalkaloid Serpasil unter dem Gesichtspunkt des psychomotorischen Parkinsonsyndroms.
Nervenarzt.
1956;
26
507-510
-
23 Hinterhuber H, Hackenberg B. Neuroleptische Turbulenzphasen. In Hinterhuber H, Schubert H, Kulhanek F, Hrsg. Schattauer Stuttgart; 1986: p. 49-56
-
24 Hinterhuber H, Haring C. Unerwünschte Wirkungen, Kontraindikationen, Überdosierung, Intoxikation. In Riederer P, Laux G, Pöldinger W, Hrsg. Neuro-Psychopharmaka. Springer Bd 4 Wien; 1992: p. 102-121
-
25
Janzarik W.
Zur Psychopathologie der Megaphenwirkung.
Nervenarzt.
1954;
25
330-335
-
26
Johnson A L, Hollister L E, Berger P A.
The anticholinergic intoxication syndrome: diagnosis and treatment.
J Clin Psychiatry.
1981;
42
313-317
-
27
Keepers G A, Clappison V J, Casey D E.
Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.
Arch Gen Psychiatry.
1983;
40
1113-1117
-
28
Koller W C.
Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy.
Cortex.
1984;
20
307-311
-
29
Kulenkampff C, Tarnow G.
Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.
Nervenarzt.
1956;
27
178-180
-
30
Larson E W, Pfenning M A, Richelson E.
Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.
Psychopharmacology.
1991;
103
162-165
-
31
McEvoy J P, McCue M, Freter S.
Replacement of chronically administered anticholinergic drugs by amantadine in out-patient management of chronic schizophrenia.
Curr Ther.
1987;
9
429-433
-
32
McEvoy J P, McCue M, Spring B. et al .
Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers.
Am J Psychiatry.
1987;
144
573-577
-
33
McEvoy J P, Freter S.
The dose-response relationship for memory impairment by anticholinergic drugs.
Compr Psychiatry.
1989;
30
135-138
-
34
Meltzer H Y, Matsabura S, Lee J C.
Classification of typical and atypical antipsychotic drugs on the basis of D- 1, D- 2 and serotonin pKi values.
J Pharmacol Ext Ther.
1989;
251
238-246
-
35 Naber D, Walther A, Kircher T. et al .Subjective effects of neuroleptics predict compliance. In Gaebel W, Awad R, eds. Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Springer Heidelberg; 1994: p. 85-98
-
36
Remington G, Bezchlibnyk-Butler K.
Management of acute antipsychotic-induced extrapyramidal syndromes.
CNS Drugs.
1996;
5 Suppl 1
21-35
-
37 Rogers D. Motor disorder in psychiatry. Towards a neurological psychiatry. Chichester: Wiley & Sons Ltd; 1992: p 65-75
-
38
Schooler N R, Kane J M.
Research diagnoses for tardive dyskinesia.
Arch Gen Psychiatry.
1982;
39
486-487
-
39
Schönecker M.
Beitrag zu der Mitteilung von Kulenkampff und Tarnow.
Nervenarzt.
1957;
28
155
-
40
Singh M M, Kay S R.
Therapeutic antagonism between anticholinergic antiparkinsonian agents and neuroleptics in schizophrenia.
Neuropsychobiol.
1979;
5
74-86
-
41
Steck H.
Le syndrome extrapyramidal et diencephalique au cours des traitements au largactil et ou serpasil.
Ann Medico-Psychologiques.
1954;
112
737-743
-
42
Taylor A E, Lang A E, Saint-Cyr A. et al .
Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.
Clin Neuropharmacol.
1991;
14
62-77
-
43
Uhrbrand L, Faurbye A.
Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy.
Psychopharmacol.
1960;
1
408-418
-
44
Van Putten T, Multipassi L R, Malkin M D.
Phenothiazine induced decompensation.
Arch Gen Psychiatry.
1974;
30
102-105
-
45
Van Putten T, May P R, Marder S R.
Akathisia with haloperidol and thiothixene.
Arch Gen Psychiatry.
1984;
41
1036-1039
-
46
Van Putten T, MarderSR.
Behavioral toxicity of antipsychotic drugs.
J Clin Psychiatry.
1987;
48 (Suppl 9)
13-19
-
47
von Dithfurt H.
Schauanfälle bei der Zwangskrankheit infolge Megapheneinwirkung.
Nervenarzt.
1957;
4
177-179
-
48
Weiden P J, Mann J J, Haas G. et al .
Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study.
Am J Psychiat.
1987;
114
1148-1153
-
49 World Health Organization. .Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990 156: 412
Prof. Dr. M. Dose
Psychiatrisches Bezirkskrankenhaus
Bräuhausstraße 5
84416 Taufkirchen
